Cybin, Inc.
(Aequitas NEO Exchange : CYBN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 2.30%54.260.9%$2601.90m
JNJJohnson & Johnson 1.43%159.340.7%$1311.17m
MRKMerck & Co., Inc. -0.77%73.320.7%$1166.64m
BMYBristol-Myers Squibb Co. 1.61%56.301.0%$773.14m
LLYEli Lilly & Co. -0.93%245.571.1%$726.06m
ABBVAbbVie, Inc. 1.72%118.881.9%$593.69m
AZNAstraZeneca Plc -1.02%54.231.0%$295.20m
NVSNovartis AG 0.06%80.000.2%$175.98m
GSKGlaxoSmithKline Plc -0.53%41.250.2%$162.67m
DRNADicerna Pharmaceuticals, Inc. 0.34%38.250.3%$148.96m
VTRSViatris, Inc. 0.00%12.200.0%$142.65m
RPRXRoyalty Pharma Plc -3.16%37.650.1%$112.47m
BFRIBiofrontera, Inc. -18.67%4.270.0%$107.17m
RGENRepligen Corp. -2.21%262.886.7%$105.50m
NVONovo Nordisk A/S 0.45%107.120.1%$85.21m

Company Profile

Cybin, Inc. is a biotechnology company that focuses on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. It operates through the following segments: Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.